Optimization of 1,3-disubstituted urea-based inhibitors of Zika virus infection

[Display omitted] Zika virus (ZIKV) has become a public health concern worldwide due to its association with congenital abnormalities and neurological diseases. To date, no effective vaccines or antiviral drugs have been approved for the treatment of ZIKV infection, and new inexpensive therapeutic o...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2019-10, Vol.29 (20), p.126626-126626, Article 126626
Main Authors: Khachatoorian, Ronik, Micewicz, Ewa D., Micewicz, Alina, French, Samuel W., Ruchala, Piotr
Format: Article
Language:English
Subjects:
Antivirals
Plaque assay
Zika inhibitors
Zika virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Zika virus (ZIKV) has become a public health concern worldwide due to its association with congenital abnormalities and neurological diseases. To date, no effective vaccines or antiviral drugs have been approved for the treatment of ZIKV infection, and new inexpensive therapeutic options are urgently needed. In this study, we have used an in vitro plaque assay to assess an antiviral activity of the second generation of anti-ZIKV compounds, based on 1,3-disubstituted (thio)urea scaffold. Several compounds in the library were found to possess excellent activity against Zika virus with IC50 values
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2019.126626